Deciphera Pharmaceuticals Stock Forecast, Price & News

+0.62 (+1.88 %)
(As of 05/11/2021 12:00 AM ET)
Today's Range
50-Day Range
52-Week Range
Volume444,890 shs
Average Volume454,639 shs
Market Capitalization$1.94 billion
P/E RatioN/A
Dividend YieldN/A
30 days | 90 days | 365 days | Advanced Chart
Receive DCPH News and Ratings via Email

Sign-up to receive the latest news and ratings for Deciphera Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

Deciphera Pharmaceuticals logo

About Deciphera Pharmaceuticals

Deciphera Pharmaceuticals, Inc., a biopharmaceutical company, develops drugs to enhance the lives of cancer patients by addressing key mechanisms of drug resistance that limit the rate and durability of response to existing cancer therapies. Its lead drug candidate is QINLOCK used for the treatment of gastrointestinal stromal tumors (GIST), as well as in INTRIGUE Phase 3 study to treat second-line GIST. The company is also developing immunokinase inhibitors comprising vimseltinib (DCC-3014) that is in Phase 1b/2 clinical trial for the treatment of tenosynovial giant cell tumors; and Rebastinib, which is in Phase 1b/2 clinical trial to treat metastatic solid tumors, as well as to investigate in combination with chemotherapy for the treatment of multiple solid tumors. In addition, it is developing DCC-3116 to treat RAS/RAF mutant cancers that is in the preclinical-stage. The company serves in the United States and Europe. Deciphera Pharmaceuticals, Inc. was founded in 2003 and is headquartered in Waltham, Massachusetts.


See More Headlines

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Current SymbolNASDAQ:DCPH
Phone(781) 209-6400
Year FoundedN/A

Sales & Book Value

Annual Sales$25 million
Book Value$10.71 per share


Net Income$-192,260,000.00




Market Cap$1.94 billion
Next Earnings Date8/3/2021 (Estimated)


Overall MarketRank

1.85 out of 5 stars

Medical Sector

121st out of 2,045 stocks

Pharmaceutical Preparations Industry

48th out of 771 stocks

Analyst Opinion: 4.4Community Rank: 2.5Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 0.6 5 -4 -3 -2 -1 -
speech bubbles
speech bubbles

Deciphera Pharmaceuticals (NASDAQ:DCPH) Frequently Asked Questions

Is Deciphera Pharmaceuticals a buy right now?

9 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Deciphera Pharmaceuticals in the last year. There are currently 1 hold rating and 8 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" Deciphera Pharmaceuticals stock.
View analyst ratings for Deciphera Pharmaceuticals
or view top-rated stocks.

What stocks does MarketBeat like better than Deciphera Pharmaceuticals?

Wall Street analysts have given Deciphera Pharmaceuticals a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Deciphera Pharmaceuticals wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

When is Deciphera Pharmaceuticals' next earnings date?

Deciphera Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Tuesday, August 3rd 2021.
View our earnings forecast for Deciphera Pharmaceuticals

How were Deciphera Pharmaceuticals' earnings last quarter?

Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH) issued its earnings results on Tuesday, May, 4th. The company reported ($1.06) earnings per share for the quarter, beating the Thomson Reuters' consensus estimate of ($1.08) by $0.02. The company earned $25.16 million during the quarter, compared to analysts' expectations of $21.35 million. The business's revenue was up 40474.2% compared to the same quarter last year.
View Deciphera Pharmaceuticals' earnings history

How has Deciphera Pharmaceuticals' stock been impacted by COVID-19 (Coronavirus)?

Deciphera Pharmaceuticals' stock was trading at $44.42 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, DCPH shares have decreased by 24.5% and is now trading at $33.53.
View which stocks have been most impacted by COVID-19

What price target have analysts set for DCPH?

9 brokers have issued 1 year target prices for Deciphera Pharmaceuticals' stock. Their forecasts range from $60.00 to $91.00. On average, they anticipate Deciphera Pharmaceuticals' share price to reach $73.00 in the next twelve months. This suggests a possible upside of 117.7% from the stock's current price.
View analysts' price targets for Deciphera Pharmaceuticals
or view top-rated stocks among Wall Street analysts.

Who are Deciphera Pharmaceuticals' key executives?

Deciphera Pharmaceuticals' management team includes the following people:
  • Mr. Steven L. Hoerter, Pres, CEO & Director (Age 50, Pay $1.02M)
  • Mr. Thomas Patrick Kelly J.D., Exec. VP, CFO & Treasurer (Age 50, Pay $777.89k)
  • Dr. Matthew L. Sherman, Exec. VP & Chief Medical Officer (Age 65, Pay $474.76k)
  • Dr. Daniel L. Flynn, Exec. VP, Chief Scientific Officer & Founder (Age 66)
  • Dr. Stephen B. Ruddy Ph.D., Chief Technical Officer (Age 57)
  • Ms. Jennifer Robinson, VP of Investor Relations
  • Mr. Jeffrey M. Held J.D., Sr. VP & Gen. Counsel
  • Ms. Caroline Chevalier, VP of HR
  • Mr. Daniel C. Martin, Chief Commercial Officer (Age 46)
  • Ms. Jama Pitman, Sr. VP of Regulatory & Quality Assurance

What is Steve Hoerter's approval rating as Deciphera Pharmaceuticals' CEO?

3 employees have rated Deciphera Pharmaceuticals CEO Steve Hoerter on Steve Hoerter has an approval rating of 100% among Deciphera Pharmaceuticals' employees. This puts Steve Hoerter in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

Who are some of Deciphera Pharmaceuticals' key competitors?

What other stocks do shareholders of Deciphera Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Deciphera Pharmaceuticals investors own include NVIDIA (NVDA), Ionis Pharmaceuticals (IONS), Vertex Pharmaceuticals (VRTX), Allena Pharmaceuticals (ALNA), Sorrento Therapeutics (SRNE), Viking Therapeutics (VKTX), Iovance Biotherapeutics (IOVA), SCYNEXIS (SCYX), Axsome Therapeutics (AXSM) and Exelixis (EXEL).

When did Deciphera Pharmaceuticals IPO?

(DCPH) raised $101 million in an initial public offering on Thursday, September 28th 2017. The company issued 6,300,000 shares at $15.00-$17.00 per share. J.P. Morgan and Piper Jaffray served as the underwriters for the IPO and JMP Securities and Nomura were co-managers.

What is Deciphera Pharmaceuticals' stock symbol?

Deciphera Pharmaceuticals trades on the NASDAQ under the ticker symbol "DCPH."

Who are Deciphera Pharmaceuticals' major shareholders?

Deciphera Pharmaceuticals' stock is owned by many different retail and institutional investors. Top institutional investors include BlackRock Inc. (6.01%), Alliancebernstein L.P. (3.44%), Kornitzer Capital Management Inc. KS (0.60%), Emerald Advisers LLC (0.50%), GW&K Investment Management LLC (0.35%) and Swiss National Bank (0.15%). Company insiders that own Deciphera Pharmaceuticals stock include Christopher John Morl, Daniel C Martin, Daniel Lee Flynn, James Arthur Bristol, Michael Douglas Taylor, New Leaf Venture Management Ii, Patricia L Allen and Thomas Patrick Kelly.
View institutional ownership trends for Deciphera Pharmaceuticals

Which institutional investors are selling Deciphera Pharmaceuticals stock?

DCPH stock was sold by a variety of institutional investors in the last quarter, including BNP Paribas Arbitrage SA, Emerald Advisers LLC, Los Angeles Capital Management LLC, Rhumbline Advisers, Blueshift Asset Management LLC, Victory Capital Management Inc., Zurcher Kantonalbank Zurich Cantonalbank , and The Manufacturers Life Insurance Company . Company insiders that have sold Deciphera Pharmaceuticals company stock in the last year include James Arthur Bristol, Michael Douglas Taylor, Patricia L Allen, and Thomas Patrick Kelly.
View insider buying and selling activity for Deciphera Pharmaceuticals
or view top insider-selling stocks.

Which institutional investors are buying Deciphera Pharmaceuticals stock?

DCPH stock was purchased by a variety of institutional investors in the last quarter, including Alliancebernstein L.P., GW&K Investment Management LLC, Kornitzer Capital Management Inc. KS, BlackRock Inc., Rafferty Asset Management LLC, Russell Investments Group Ltd., State of New Jersey Common Pension Fund D, and Otter Creek Advisors LLC.
View insider buying and selling activity for Deciphera Pharmaceuticals
or or view top insider-buying stocks.

How do I buy shares of Deciphera Pharmaceuticals?

Shares of DCPH can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Deciphera Pharmaceuticals' stock price today?

One share of DCPH stock can currently be purchased for approximately $33.53.

How much money does Deciphera Pharmaceuticals make?

Deciphera Pharmaceuticals has a market capitalization of $1.94 billion and generates $25 million in revenue each year. The company earns $-192,260,000.00 in net income (profit) each year or ($4.48) on an earnings per share basis.

How many employees does Deciphera Pharmaceuticals have?

Deciphera Pharmaceuticals employs 350 workers across the globe.

What is Deciphera Pharmaceuticals' official website?

The official website for Deciphera Pharmaceuticals is

Where are Deciphera Pharmaceuticals' headquarters?

Deciphera Pharmaceuticals is headquartered at 200 SMITH STREET, Waltham MA, 02451.

How can I contact Deciphera Pharmaceuticals?

Deciphera Pharmaceuticals' mailing address is 200 SMITH STREET, Waltham MA, 02451. The company can be reached via phone at (781) 209-6400 or via email at [email protected]

This page was last updated on 5/11/2021 by Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.